Valuation: Galapagos NV

Market Cap 1.57B 1.81B 1.81B 1.46B 1.34B 2.54B 173B 2.58B 17.25B 6.77B 85.96B 6.79B 6.64B 288B P/E 2026 *
-11.2x
P/E 2027 * -8.45x
Enterprise Value -411M -473M -473M -383M -351M -663M -45.13B -673M -4.51B -1.77B -22.47B -1.78B -1.74B -75.34B EV / Sales 2026 *
-28.9x
EV / Sales 2027 * -9.14x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.50%+1.05%+59.43%+103.27% 27.82B
Weighted average by Cap. -1.60%+2.03%+76.87%+128.10%

Financials

2026 *2027 *
Net sales 14.24M 16.38M 16.38M 13.25M 12.17M 22.98M 1.56B 23.34M 156M 61.32M 779M 61.52M 60.17M 2.61B 46.09M 53.02M 53.02M 42.9M 39.39M 74.38M 5.06B 75.53M 506M 198M 2.52B 199M 195M 8.45B
Net income -811M -933M -933M -755M -693M -1.31B -89.03B -1.33B -8.89B -3.49B -44.32B -3.5B -3.43B -149B -238M -274M -274M -221M -203M -384M -26.11B -390M -2.61B -1.02B -13B -1.03B -1B -43.59B
Net Debt -1.98B -2.28B -2.28B -1.85B -1.69B -3.2B -218B -3.25B -21.76B -8.54B -108B -8.57B -8.38B -364B -1.99B -2.29B -2.29B -1.86B -1.7B -3.22B -219B -3.27B -21.87B -8.58B -109B -8.61B -8.42B -365B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B